Condition
Recurrent Primary Peritoneal Carcinoma clinical trials and research
As of November 12, 2026, Find a Trial lists 10 Recurrent Primary Peritoneal Carcinoma clinical trials that are recruiting, at sites in 2 countries (most in United States (10), Puerto Rico (1)). By phase: Phase 2 (5), Phase 1 (3). The most active sponsors are Roswell Park Cancer Institute (3), M.D. Anderson Cancer Center (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 10Clinical trials
- 2Countries
Newest Recurrent Primary Peritoneal Carcinoma clinical trials
All recruiting trials (10)
-
Automated physical activity program for cancer patients
This study is testing whether a personalized exercise program using wearable technology can help cancer patients be more active compared to regular exercise advice.
-
Using MUC1-activated T cells to treat resistant ovarian cancer
This study is testing a new treatment using specially designed immune cells to see if they can help people with tough-to-treat ovarian cancer feel better and improve their health.
-
Investigating blood cancer risks in patients with ovarian and other solid tumors
This study is trying to see if certain cancer treatments for ovarian and other solid tumors can increase the risk of blood cancers in patients.
-
Targeted therapy for advanced solid tumors based on genetic testing
This study is testing whether matching patients with advanced solid tumors to specific treatments based on their genetic makeup can improve their outcomes when standard options have failed.
-
Combining pembrolizumab and bevacizumab with an immune booster for recurrent ovarian cancer
This study is testing a new combination of two cancer drugs, pembrolizumab and bevacizumab, with or without an immune booster, to see if it helps people with recurrent ovarian cancer feel better and live longer.
-
Combining APL-2 with Pembrolizumab and Bevacizumab for Recurrent Ovarian Cancer
This study is testing if a new treatment combining APL-2 with pembrolizumab and bevacizumab can help people with recurrent ovarian cancer feel better and live longer compared to just using bevacizumab alone.
-
Using abemaciclib to treat recurrent ovarian or endometrial cancer
This study is testing if the drug abemaciclib can help people with recurrent ovarian or endometrial cancer stay cancer-free for at least 16 weeks.
-
Combining ONC201 with Paclitaxel for Ovarian Cancer Treatment
This study is testing if combining a new drug called ONC201 with paclitaxel can help people with hard-to-treat ovarian cancer feel better and live longer.
-
Combining talazoparib with radiation therapy for recurrent gynecologic cancers
This study is testing if combining a drug called talazoparib with radiation therapy can safely help people with recurrent gynecologic cancers feel better.
-
Imaging with a new radioactive tracer for solid tumors
This study is testing a new imaging method using a special radioactive tracer to see if it can help find tumor cells in patients with solid tumors like ovarian and breast cancers, while also looking at how safe it is and how it relates to certain genetic factors.
Related topics
Quick answers
How many Recurrent Primary Peritoneal Carcinoma clinical trials are recruiting right now?
10, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (10 trials), Puerto Rico (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 5, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.